UNSPSC 85812137: Introduction of monoclonal antibody into nose, percutaneous approach

This classification denotes the group of activities that yields a administrative intervention or procedure to introduction of monoclonal antibody into nose, percutaneous approach. This administrative intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 3E0930M

UNSPSC 85812137 Introduction of monoclonal antibody into nose, percutaneous approach is a Commodity code that does not reflect the recent state and local procurement activity tagged under it. The opportunities posted under this code span virtual urgent care services, medical director positions, emergency medical technician staffing, occupational health screening, cancer registry services, retinal imaging devices, nursing home operations, employee wellness platforms, opioid use disorder treatment and recovery, behavioral health crisis services, and inmate healthcare — none of which involve monoclonal antibody administration. The nominal UNSPSC code appears misapplied or overcast across a broad set of health services that fall outside the specific procedural scope the code name suggests.

State and local issuing bodies posting under this code include health plans (Inland Empire Health Plan in California), county health authorities (DeKalb County, Georgia; Nevada Health Authority; Ventura County; Solano County), municipal health systems and fire departments (San Mateo Medical Center; Boulder County Sheriff; City of Ocala; Sarasota County Fire), county behavioral health divisions (Santa Clara County, Rockland County, Fairfax County), school districts (Parkway School District), transit authorities and purchasing cooperatives (Sourcewell, H-GAC, Region 7), and state agencies (Colorado Department of Human Services, Texas Health and Human Services Commission, Nevada Health Authority, Illinois Secretary of State, New Jersey Department of Health). Recent solicitations span RFPs, RFQs, IFBs, and RFIs issued between late July 2026 and mid-October 2026, with response deadlines clustered from August through December 2026. Geographic activity concentrates in California (San Mateo County, Inland Empire, Los Alamos County, Ventura County, Santa Clara County), Nevada (statewide PACE and rural value-based care initiatives), Colorado (nursing home beds for complex behavioral presentations), Texas (multiple state-supported living centers and health agencies), Georgia (DeKalb County and Forsyth County occupational health), Florida (Sarasota County fire EMS medical director, San Mateo Cancer Registry, Brevard County histology), Kansas (Sedgwick County and Wichita opioid use disorder programs), with scattered additional activity in Arizona, Illinois, Missouri, New Jersey, New York, Oregon, and the District of Columbia. This code shows no coherent recent procurement narrative tied to monoclonal antibodies or the specific percutaneous-nasal route of administration the Commodity name specifies; the activity reflects state and local healthcare service delivery across primary care, specialty care, occupational health, behavioral health, and emergency services broadly rather than a targeted biologic-therapy or drug-administration niche.